Idorsia Ltd (IDRSF)
ValueMarkers Composite Index
DCF data not available
Idorsia Ltd (IDRSF) — VMCI valuation read
IDRSF prints VMCI 38/100 inside the Healthcare sector, where the median sits at 50. The 12-point below-median delta is the cleanest single-number summary of Idorsia Ltd's composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.
On IDRSF, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** IDRSF trades at 20.0x earnings, 11% above the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 3.2x is the binding constraint on the bear case; that is the risk line for Idorsia Ltd on the trailing financials.
IDRSF rose 1.2% over the trailing 7 days, with a -14.0% read on a 30-day basis.
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.
Browse More
Key metrics explained
Definitions, formulas, and how ValueMarkers calculates each indicator used in IDRSF’s VM Score.
Explore More
Popular Stocks
- Apple (AAPL)Apple value analysis · VMCI score, DCF, MOS
- Microsoft (MSFT)Microsoft value analysis · 120 fundamental indicators
- Alphabet (GOOGL)Alphabet/Google value analysis
- Amazon (AMZN)Amazon intrinsic value and growth profile
- NVIDIA (NVDA)NVIDIA quality, growth, and risk analysis
- Meta Platforms (META)Meta value analysis · VMCI breakdown
- Berkshire Hathaway (BRK.B)Berkshire quality + integrity breakdown
- Johnson & Johnson (JNJ)JNJ dividend quality analysis
- Visa (V)Visa moat, growth, and valuation
- JPMorgan Chase (JPM)JPM financials quality analysis
- Coca-Cola (KO)KO dividend king analysis
- Procter & Gamble (PG)PG dividend king fundamentals
Browse ETFs
- All ETFsTop 100 ETFs by AUM with VMCI-Composite scores
- SPY · S&P 500Broad-market ETF holdings analysis
- VOO · Vanguard S&P 500Low-cost S&P 500 exposure
- QQQ · Nasdaq 100Large-cap growth ETF analysis
- VTI · Total US MarketTotal US equity market ETF
- SCHD · Dividend ETFDividend-focused ETF holdings breakdown
- VYM · High Dividend YieldHigh-yield US dividend ETF
- DGRO · Dividend GrowthDividend growth ETF analysis
- XLK · Tech SectorTechnology sector ETF holdings
- VNQ · Real EstateUS REIT-focused ETF analysis
- GLD · GoldPhysical-gold-backed ETF
- ARKK · Disruptive InnovationThematic growth ETF holdings
Dividend Stocks
- All Dividend Stocks500+ dividend payers with safety scoring
- Dividend Kings50+ years of consecutive dividend growth
- Dividend Aristocrats25+ years of growth · S&P 500 members
- Dividend Contenders10-24 years of dividend growth
- Dividend Challengers5-9 years of dividend growth
- Safe-Yield DividendsQuality > 70 · low-risk dividend payers
- High-Yield DividendsStocks yielding 5%+ with payout health checks
- Dividend Growth10%+ five-year dividend CAGR
- Foreign DividendsNon-US dividend ADRs with VMCI scores
- Coca-Cola (KO) DividendKO dividend deep dive · DRIP projection
- JNJ Dividend AnalysisJohnson & Johnson dividend safety profile
- Procter & Gamble (PG) DividendPG dividend king status
Financial Glossary
- All Definitions120+ value-investing indicators explained
- Piotroski F-ScoreFinancial-strength signal 0-9
- Altman Z-ScoreBankruptcy-distress indicator
- Beneish M-ScoreEarnings-manipulation detection
- Margin of SafetyGraham's discount to intrinsic value
- DCF Intrinsic ValueDiscounted cash-flow valuation
- Graham NumberDefensive-investor fair-value formula
- P/E Ratio (TTM)Trailing price-to-earnings multiple
- EV/EBITDAEnterprise-value to EBITDA multiple
- FCF YieldFree-cash-flow per share / price
- ROICReturn on invested capital · quality signal
- ROIC-WACC SpreadEconomic profit signal
- WACCWeighted average cost of capital
- Dividend YieldAnnual dividend per share / price
- Owner EarningsBuffett's preferred cash-flow metric
Compare Competitors
- All ComparisonsCompare 67+ stock analysis tools
- vs GuruFocusDetailed feature and pricing comparison
- vs TIKRSide-by-side platform comparison
- vs MorningstarCompare analysis capabilities
- vs FinvizScreener comparison and review
- vs Seeking AlphaResearch platform comparison
- vs Simply Wall StVisual analysis comparison
- vs Yahoo FinanceFree tool comparison
- vs ZacksEarnings rank vs fundamental analysis
- vs StockopediaStockRanks vs DCF comparison
- vs Stock RoverPortfolio analytics comparison
- vs KoyfinTerminal-style tool comparison
- vs TradingViewCharting platform comparison
- vs Alpha SpreadValuation tool comparison
- vs WisesheetsExcel/Sheets add-in comparison
- vs MacroaxisData portal vs analysis platform
- vs Old School ValueGraham-style analysis comparison
- vs TIKR TerminalData terminal vs screener comparison